Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open‐Label Trial
Objective Patients with uncontrolled gout have few treatment options. Pegloticase lowers serum urate (SU) levels, but antidrug antibodies limit SU‐lowering response and increase infusion reaction (IR) risk. Methotrexate (MTX) cotherapy increases pegloticase response rates and lowers IR risk in peglo...
Saved in:
Main Authors: | Orrin M. Troum, John K. Botson, Katie Obermeyer, Bo Chao, Yang Song, Jennifer Zarzoso, Kjerstina Gutierrez, Supra Verma, Lissa Padnick‐Silver, Brian LaMoreaux |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11789 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis
by: Robert J. Morlock, et al.
Published: (2024-11-01) -
Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
by: Linlin Ma, et al.
Published: (2021-01-01) -
Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study
by: Lehana Thabane, et al.
Published: (2022-06-01) -
Case Report: Intradural gout tophi without systemic gout symptoms
by: Peidong Qing, et al.
Published: (2025-02-01) -
Methotrexate Induced Pancytopenia
by: Fernando Gonzalez-Ibarra, et al.
Published: (2014-01-01)